These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 38757223)

  • 21. Hepatocellular carcinoma and non-alcoholic steatohepatitis: The state of play.
    Charrez B; Qiao L; Hebbard L
    World J Gastroenterol; 2016 Feb; 22(8):2494-502. PubMed ID: 26937137
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preclinical models of non-alcoholic steatohepatitis leading to hepatocellular carcinoma.
    Green CD; Spiegel S
    Adv Biol Regul; 2023 Jan; 87():100925. PubMed ID: 36706611
    [TBL] [Abstract][Full Text] [Related]  

  • 23. TAZ-induced Cybb contributes to liver tumor formation in non-alcoholic steatohepatitis.
    Wang X; Zeldin S; Shi H; Zhu C; Saito Y; Corey KE; Osganian SA; Remotti HE; Verna EC; Pajvani UB; Schwabe RF; Tabas I
    J Hepatol; 2022 Apr; 76(4):910-920. PubMed ID: 34902531
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oxidative stress and Liver X Receptor agonist induce hepatocellular carcinoma in Non-alcoholic steatohepatitis model.
    Shimizu Y; Tamura T; Kemmochi A; Owada Y; Ozawa Y; Hisakura K; Matsuzaka T; Shimano H; Nakano N; Sakashita S; Oda T; Ohkohchi N
    J Gastroenterol Hepatol; 2021 Mar; 36(3):800-810. PubMed ID: 32870526
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A simple diet- and chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver cancer.
    Tsuchida T; Lee YA; Fujiwara N; Ybanez M; Allen B; Martins S; Fiel MI; Goossens N; Chou HI; Hoshida Y; Friedman SL
    J Hepatol; 2018 Aug; 69(2):385-395. PubMed ID: 29572095
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Unraveling the underlying pathogenic factors driving nonalcoholic steatohepatitis and hepatocellular carcinoma: an in-depth analysis of prognostically relevant gene signatures in hepatocellular carcinoma.
    Ni Y; Lu M; Li M; Hu X; Li F; Wang Y; Xue D
    J Transl Med; 2024 Jan; 22(1):72. PubMed ID: 38238845
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of the Cell Death Pathway in Nonalcoholic Steatohepatitis (NASH)-Related Hepatocarcinogenesis Is Associated with Histone H4 lysine 16 Deacetylation.
    de Conti A; Dreval K; Tryndyak V; Orisakwe OE; Ross SA; Beland FA; Pogribny IP
    Mol Cancer Res; 2017 Sep; 15(9):1163-1172. PubMed ID: 28512251
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Imbalance in ALR ubiquitination accelerates the progression of nonalcoholic steatohepatitis to hepatocellular carcinoma.
    Zheng M; Ai Z; Guo Y; Chen Y; Xie P; An W
    Oncogene; 2023 Jan; 42(4):308-321. PubMed ID: 36434180
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Supervised learning reveals circulating biomarker levels diagnostic of hepatocellular carcinoma in a clinically relevant model of non-alcoholic steatohepatitis; An OAD to NASH.
    Hwang A; Shi C; Zhu E; Naaz F; Zhou P; Rasheed Z; Liu M; Jung LS; Duan B; Li J; Jiang K; Paka L; Gadhiya SV; Dana D; Ali Q; Yamin MA; Goldberg ID; Narayan P
    PLoS One; 2018; 13(6):e0198937. PubMed ID: 29944670
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparisons between non-alcoholic steatohepatitis and alcohol-related hepatocellular carcinoma.
    Kumar R; Goh BG; Kam JW; Chang PE; Tan CK
    Clin Mol Hepatol; 2020 Apr; 26(2):196-208. PubMed ID: 31914720
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bioinformatics analysis reveals novel core genes associated with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Feng G; Li XP; Niu CY; Liu ML; Yan QQ; Fan LP; Li Y; Zhang KL; Gao J; Qian MR; He N; Mi M
    Gene; 2020 Jun; 742():144549. PubMed ID: 32184169
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Semaglutide reduces tumor burden in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH-HCC with advanced fibrosis.
    Hansen HH; Pors S; Andersen MW; Vyberg M; Nøhr-Meldgaard J; Nielsen MH; Oró D; Madsen MR; Lewinska M; Møllerhøj MB; Madsen AN; Feigh M
    Sci Rep; 2023 Dec; 13(1):23056. PubMed ID: 38155202
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antagonizing STK25 Signaling Suppresses the Development of Hepatocellular Carcinoma Through Targeting Metabolic, Inflammatory, and Pro-Oncogenic Pathways.
    Kurhe Y; Caputo M; Cansby E; Xia Y; Kumari S; Anand SK; Howell BW; Marschall HU; Mahlapuu M
    Cell Mol Gastroenterol Hepatol; 2022; 13(2):405-423. PubMed ID: 34624527
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of osteopontin on the development of non-alcoholic liver disease and related hepatocellular carcinoma.
    Nardo AD; Grün NG; Zeyda M; Dumanic M; Oberhuber G; Rivelles E; Helbich TH; Markgraf DF; Roden M; Claudel T; Trauner M; Stulnig TM
    Liver Int; 2020 Jul; 40(7):1620-1633. PubMed ID: 32281248
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discovering Biomarkers for Non-Alcoholic Steatohepatitis Patients with and without Hepatocellular Carcinoma Using Fecal Metaproteomics.
    Sydor S; Dandyk C; Schwerdt J; Manka P; Benndorf D; Lehmann T; Schallert K; Wolf M; Reichl U; Canbay A; Bechmann LP; Heyer R
    Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012106
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis.
    Pinyol R; Torrecilla S; Wang H; Montironi C; Piqué-Gili M; Torres-Martin M; Wei-Qiang L; Willoughby CE; Ramadori P; Andreu-Oller C; Taik P; Lee YA; Moeini A; Peix J; Faure-Dupuy S; Riedl T; Schuehle S; Oliveira CP; Alves VA; Boffetta P; Lachenmayer A; Roessler S; Minguez B; Schirmacher P; Dufour JF; Thung SN; Reeves HL; Carrilho FJ; Chang C; Uzilov AV; Heikenwalder M; Sanyal A; Friedman SL; Sia D; Llovet JM
    J Hepatol; 2021 Oct; 75(4):865-878. PubMed ID: 33992698
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacological inhibition of CFTR attenuates nonalcoholic steatohepatitis (NASH) progression in mice.
    Rajak S; Tewari A; Raza S; Gupta P; Chakravarti B; Anjum B; Tripathi M; Singh BK; Yen PM; Goel A; Ghosh S; Sinha RA
    Biochim Biophys Acta Mol Basis Dis; 2023 Apr; 1869(4):166662. PubMed ID: 36754244
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A new NASH model in aged mice with rapid progression of steatohepatitis and fibrosis.
    Li X; Lu Y; Liang X; Zhou X; Li D; Zhang Z; Niu Y; Liu S; Ye L; Zhang R
    PLoS One; 2023; 18(5):e0286257. PubMed ID: 37228085
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Blocking sphingosine 1-phosphate receptor 2 accelerates hepatocellular carcinoma progression in a mouse model of NASH.
    Yoshida T; Tsuchiya A; Kumagai M; Takeuchi S; Nojiri S; Watanabe T; Ogawa M; Itoh M; Takamura M; Suganami T; Ogawa Y; Terai S
    Biochem Biophys Res Commun; 2020 Oct; 530(4):665-672. PubMed ID: 32768187
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of necroptosis in chronic hepatic inflammation and fibrosis in a mouse model of increased oxidative stress.
    Mohammed S; Nicklas EH; Thadathil N; Selvarani R; Royce GH; Kinter M; Richardson A; Deepa SS
    Free Radic Biol Med; 2021 Feb; 164():315-328. PubMed ID: 33429022
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.